Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017

Citations

WEB OF SCIENCE

5
Citations

SCOPUS

5

초록

The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

키워드

Clinical practice guideline; Diabetes mellitus, type 2; Hypoglycemic agents; Insulin; Korea; PEPTIDE-1 RECEPTOR AGONIST; ORAL ANTIDIABETIC DRUGS; GLYCEMIC CONTROL; BASAL INSULIN; PREMIXED INSULIN; BOLUS INSULIN; SULFONYLUREA; METFORMIN; REGIMENS; MANAGEMENT
제목
Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017
저자
Lee, Byung-Wan; Kim, Jin Hwa; Ko, Seung-Hyun; Hur, Kyu Yeon; Kim, Nan-Hee; Rhee, Sang Youl; Kim, Hyun Jin; Moon, Min Kyong; Park, Seok-O; Choi, Kyung Mook
DOI
10.3904/kjim.2017.314
발행일
2017-11
유형
Review
저널명
The Korean Journal of Internal Medicine
권
32
호
6
페이지
967 ~ 973